Evidence map›Paper›PMID 28494180›Full record

ArticleCell cycle (Georgetown, Tex.)2017

Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.

Kentaro Igarashi, Kei Kawaguchi, Takashi Murakami, Tasuku Kiyuna, Kentaro Miyake, Scott D Nelson, Sarah M Dry, Yunfeng Li, Jane Yanagawa, Tara A Russell and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Review
  3. Recombinant AttenuatedCancers · 2022
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Tumor-targetingHeliyon · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Kentaro Igarashia AntiCancer, Inc. , San Diego , CA , USA.ORCID http://orcid.org/0000-0002-4680-4317
Kei Kawaguchia AntiCancer, Inc. , San Diego , CA , USA.
Takashi Murakamia AntiCancer, Inc. , San Diego , CA , USA.
Tasuku Kiyunaa AntiCancer, Inc. , San Diego , CA , USA.
Kentaro Miyakea AntiCancer, Inc. , San Diego , CA , USA.
Scott D Nelsond Department of Pathology , University of California Los Angeles , CA , USA.
Sarah M Dryd Department of Pathology , University of California Los Angeles , CA , USA.
Yunfeng Lid Department of Pathology , University of California Los Angeles , CA , USA.
Jane Yanagawae Division of Surgical Oncology , University of California , Los Angeles , CA , USA.
Tara A Russelle Division of Surgical Oncology , University of California , Los Angeles , CA , USA.ORCID http://orcid.org/0000-0002-3912-3601
Arun S Singhf Division of Hematology-Oncology , University of California , Los Angeles , CA , USA.
Norio Yamamotoc Department of Orthopaedic Surgery , Kanazawa University , Kanazawa , Japan.
Katsuhiro Hayashic Department of Orthopaedic Surgery , Kanazawa University , Kanazawa , Japan.
Hiroaki Kimurac Department of Orthopaedic Surgery , Kanazawa University , Kanazawa , Japan.
Shinji Miwac Department of Orthopaedic Surgery , Kanazawa University , Kanazawa , Japan.
Hiroyuki Tsuchiyac Department of Orthopaedic Surgery , Kanazawa University , Kanazawa , Japan.
Fritz C Eilbere Division of Surgical Oncology , University of California , Los Angeles , CA , USA.ORCID http://orcid.org/0000-0003-3336-9333
Robert M Hoffmana AntiCancer, Inc. , San Diego , CA , USA.
University of California, Los Angeles · USKanazawa University · JPUniversity of California San Diego · US

Funding

Establishment of a patient-like mouse models of soft-tissue sarcoma sub-typesR43CA213649 · NCI · ANTICANCER, INC. · PI HOFFMAN, ROBERT M · 2017 to 2017
$225k
6 · The paper itself

Abstract

Previously, a patient-derived orthotopic xenograft (PDOX) model was established with a lung metastasis from an osteosarcoma patient which developed after adjuvant cisplatinum (CDDP) treatment. In this model, we previously demonstrated the efficacy of trabectedin (TRAB) and temozolomide (TEM) compared with CDDP. In the present report, osteosarcoma tissue was implanted orthotopically in the distal femur of mice which were randomized into the following groups when tumor volume reached approximately 100 mm

Indexed as

Salmonella typhimuriumAdolescentAnimalsBone NeoplasmsCisplatinDrug Resistance, NeoplasmHeterograftsHumansInjections, Intra-ArterialLung NeoplasmsMice, NudeNeoplasm TransplantationOsteosarcomaTumor BurdenXenograft Model Antitumor AssaysCisplatincisplatinum-resistantintra-arterialOsteosarcomaPDOXrecurrentSalmonella typhimurium A1-R

Identifiers

PMID28494180
PMCPMC5499917
OpenAlexW2612978847

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.